Cancer clinical trials in the region Nouvelle-Aquitaine
428 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07318558
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Clear cell carcinoma
Required FIGO stages
Stage III
Stage IV
Required disease stage
Localized
Required HRD statuses
HRD Negative
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Surgery
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT04928846
#2023-505749-14-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Excluded genetic anomalies
EGFR
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Antibody Drug Conjugates (ADC)
12 recruiting sites
Abbvie
Phase 3
Lung cancer
#NCT06890598
#2024-512302-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Radiotherapy
Excluded genetic anomalies
ALK
EGFR
14 recruiting sites
Eli Lilly et compagnie
Phase 3
Lung cancer
#NCT06890598
#2024-512302-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Surgery
Immunotherapy
Chemotherapy
Excluded genetic anomalies
ALK
EGFR
14 recruiting sites
Eli Lilly et compagnie
Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT06960577
Required histologic types
Invasive bladder cancer
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
14 recruiting sites
AstraZeneca
Phase 3
Multiple myeloma
#NCT07258511
#2025-522007-18-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
6 recruiting sites
Janssen
Phase 3
Lung cancer
#NCT06692738
#2024-514281-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
8 recruiting sites
AstraZeneca
Phase 3
Lung cancer
#NCT06627647
#2024-515008-38-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
8 recruiting sites
AstraZeneca
Phase 3
Lung cancer
#NCT06899126
#2024-515658-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required PDL1 statuses
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
HRAS
KRAS G12C
KRAS non G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
Antibody Drug Conjugates (ADC)
16 recruiting sites
Daiichi Sankyo
Phase 3
Stomach and esophageal cancer
#NCT06731478
#2024-513122-27-00
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
14 recruiting sites
Daiichi Sankyo